You are here

  • Home
  • Archive
  • Volume 12, Issue 12
  • Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant reci…

Article info

Article menu
Renal medicine
Protocol
Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients

Authors

  • Julian Singer Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Matthew Tunbridge Central and Northern Adelaide Renal and Transplantation Service (CNARTS), Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Griffith B Perkins School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, AustraliaImmunology, SA Pathology, Central Adelaide Local Health Network, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Tania Salehi Central and Northern Adelaide Renal and Transplantation Service (CNARTS), Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Tracey Ying Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Huiling Wu Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • P Toby Coates Central and Northern Adelaide Renal and Transplantation Service (CNARTS), Royal Adelaide Hospital, Adelaide, South Australia, AustraliaDiscipline of Medicine, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Steven J Chadban Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, AustraliaDepartment of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Steven J Chadban; steve.chadban{at}health.nsw.gov.au
View Full Text

Citation

Singer J, Tunbridge M, Perkins GB, et al
Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
BMJ Open 2022;12:e062747. doi: 10.1136/bmjopen-2022-062747

Publication history

  • Received March 10, 2022
  • Accepted October 16, 2022
  • First published December 1, 2022.
Online issue publication 
December 01, 2022
Previous versions
Review history

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.